Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
Comments Off on Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
April 25, 2026
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Clinical Summary The U.S. Drug Enforcement…
Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act
Comments Off on Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act
April 19, 2026
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyMental Health Clinical Summary The Drug Enforcement…
Policy Watch: 20 Regulatory Updates — March 10, 2026
Policy WatchMarch 10, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Regulations.gov Schedules of…